Abstract
In about 20–30% of all women with breast cancer, an increased number of cases of breast cancer can be observed in their family history. However, currently, only 5–10% of all breast cancer cases can be attributed to a pathogenic gene alteration. Molecular genetic diagnostics underwent enormous development within the last 10 years. Next-generation sequencing approaches allow increasingly extensive analyses resulting in the identification of additional candidate genes. In the present work, the germline molecular diagnostic analysis of a cohort of 228 patients with suspected hereditary breast and ovarian cancer syndrome (HBOC) was evaluated. The 27 pathogenic gene variants initially detected are listed, and their distribution in the high-risk BRCA1 and BRCA2 genes is presented in this study. In ten high-risk patients, in whom, to date, no pathogenic variant could be detected, an extended genetic analysis of previously not considered risk genes was performed. Three variants of uncertain significance and one pathogenic variant could be described. This proves the importance of extended analysis using current molecular genetic methods.
Subject
Genetics(clinical),Genetics
Reference60 articles.
1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) S3-Leitlinie Früherkennung, Diagnose, Therapie Und Nachsorge Des Mammakarzinoms, Version 4.1, AWMF Registernummer: 032-045OLhttp://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
2. Die TruRisk® Genpanel-Analyse Bei Familiärem Brust-Und Eierstockkrebshttps://www.konsortium-familiaerer-brustkrebs.de/betreuungskonzept/molekulare-diagnostik/truriskr-genpanel-analyse/
3. Familiärer Brustkrebs – empirische Erkrankungsrisiken und Risikoberechnungsmodelle
4. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献